- Home
- VSTM vs URGN Comparison
VSTM vs URGN Comparison
Compare VSTM & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- URGN
- Stock Information
- Founded
- VSTM 2010
- URGN 2004
- Country
- VSTM United States
- URGN United States
- Employees
- VSTM N/A
- URGN N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- VSTM Health Care
- URGN Health Care
- Exchange
- VSTM Nasdaq
- URGN Nasdaq
- Market Cap
- VSTM 425.9M
- URGN 463.2M
- IPO Year
- VSTM 2012
- URGN 2017
- Fundamental
- Price
- VSTM $6.06
- URGN $4.75
- Analyst Decision
- VSTM Strong Buy
- URGN Strong Buy
- Analyst Count
- VSTM 9
- URGN 8
- Target Price
- VSTM $13.63
- URGN $27.92
- AVG Volume (30 Days)
- VSTM 2.1M
- URGN 2.4M
- Earning Date
- VSTM 05-13-2025
- URGN 05-12-2025
- Dividend Yield
- VSTM N/A
- URGN N/A
- EPS Growth
- VSTM N/A
- URGN N/A
- EPS
- VSTM N/A
- URGN N/A
- Revenue
- VSTM $10,000,000.00
- URGN $91,871,000.00
- Revenue This Year
- VSTM $106.87
- URGN $35.06
- Revenue Next Year
- VSTM $312.95
- URGN $112.94
- P/E Ratio
- VSTM N/A
- URGN N/A
- Revenue Growth
- VSTM N/A
- URGN 8.98
- 52 Week Low
- VSTM $2.10
- URGN $3.42
- 52 Week High
- VSTM $9.10
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- VSTM 47.31
- URGN 30.12
- Support Level
- VSTM $7.60
- URGN $3.61
- Resistance Level
- VSTM $9.10
- URGN $4.25
- Average True Range (ATR)
- VSTM 0.88
- URGN 0.81
- MACD
- VSTM -0.09
- URGN -0.33
- Stochastic Oscillator
- VSTM 33.16
- URGN 12.94
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.